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Abstract 
Background: A significant association is known between increased glycaemic variability and mortality in critical 
patients. To ascertain whether glycaemic profiles during the first week after liver transplantation might be associated 
with long‑term mortality in these patients, by analysing whether diabetic status modified this relationship.
Method: Observational long‑term survival study includes 642 subjects undergoing liver transplantation from July 
1994 to July 2011. Glucose profiles, units of insulin and all variables with influence on mortality are analysed using 
joint modelling techniques.
Results: Patients registered a survival rate of 85% at 1 year and 65% at 10 years, without differences in mortal‑
ity between patients with and without diabetes. In glucose profiles, however, differences were observed between 
patients with and without diabetes: patients with diabetes registered lower baseline glucose values, which gradually 
rose until reaching a peak on days 2–3 and then subsequently declined, diabetic subjects started from higher values 
which gradually decreased across the first week. Patients with diabetes showed an association between mortality and 
age, Model for End‑Stage Liver Disease score (MELD) score and hepatitis C virus; among non‑diabetic patients, mortal‑
ity was associated with age, body mass index, malignant aetiology, red blood cell requirements and parenteral nutri‑
tion. Glucose profiles were observed to be statistically associated with mortality among patients without diabetes 
(P = 0.022) but not among patients who presented with diabetes prior to transplantation (P = 0.689).
Conclusions: Glucose profiles during the first week after liver transplantation are different in patients with and 
without diabetes. While glucose profiles are associated with long‑term mortality in patients without diabetes, after 
adjusting for potential confounding variables such as age, cause of transplantation, MELD, nutrition, immunosuppres‑
sive drugs, and units of insulin administered, this does not occur among patients with diabetes.
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Background
Orthotopic liver transplantation (OLT) is the established 
treatment for end-stage liver disease and acute fulminant 
hepatic failure, and more than 100,000 OLTs have been 
performed in Europe [1]. Advances in both medical man-
agement and surgical techniques have led to an increase 
in the number of long-term survivors [2].
Alterations in glucose metabolism are common among 
patients undergoing surgery, and are associated with 
increased risk of mortality and morbidity [3]. These 
abnormalities, particularly hyperglycaemia, are also 
common in critically ill patients, even those without a 
diagnosis of diabetes. Hyperglycaemia associated with 
critical illness is commonly regarded as an extreme form 
of “stress hyperglycaemia”, typically attributed to insulin 
resistance caused by endogenous and exogenous cat-
echolamines and glucocorticoids. High levels of circu-
lating free fatty acids inhibit peripheral glucose uptake 
and use, causing hepatic steatosis, which impairs liver 
glucose regulation in the critically ill [4, 5]. In addition, 
blood glucose concentrations vary markedly in critically 
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insulin infusions, and blood glucose values and incidence 
of hyperglycaemia have a circadian rhythm in critically 
ill patients [6]. Indeed, blood glucose variability can be 
quite different in the presence of the same mean blood 
glucose value.
Several researchers have consistently reported a sig-
nificant association between increased glycaemic vari-
ability and worse outcome in critically ill patients [7–12]. 
In their analyses, blood glucose variability is measured 
by using standard deviation, percentile values and suc-
cessive changes in blood glucose, and by calculating the 
coefficient of variation. It is, however, recognised that, 
compared to the use of only single-moment biomarker 
values, serial biomarker evaluations may carry important 
additional information as regards prognosis of the dis-
ease under study.
We hypothesised that postoperative blood glucose con-
centrations would independently predict mortality in 
patients undergoing OLT. During patients’ stay in hospi-
tal, clinicians use longitudinal glucose measurements to 
gain a better understanding of disease dynamics. Accord-
ingly, this study sought to investigate the ability of post-
operative glucose profiles measured for 7 days to predict 
mortality in patients who underwent OLT, differentiating 
between those with and those without pre-existing dia-
betes mellitus. The relationship between glucose profiles 
and risk of death was modelled using flexible joint mod-
elling of longitudinal data and time-to-event analysis.
Patients and methods
We conducted an observational study of 642 patients 
undergoing liver transplantation at a single, tertiary care 
transplant hospital from July 1994 to July 2011. Patients 
were followed up until 12 July 2012. The following exclu-
sion criteria were applied: any patient who had a previous 
organ transplant, had any other invasive surgery at the 
date of transplantation, had incomplete medical records 
or had died within the first 72  h. Finally, a total of 632 
patients were available for study. Data were drawn from 
hospital medical records and transplant database. Pre-
transplant variables were recorded, including age, gen-
der, body mass index (BMI), indication for OLT, Model 
for End-stage Liver Disease (MELD) score, haemoglobin, 
haematocrit, platelet count, prothrombin time, serum 
total bilirubin levels, serum creatinine levels, fasting 
blood glucose and prior diagnosis of diabetes. In addi-
tion, the following surgical variables were studied: surgi-
cal technique; transfusion requirements; operating time; 
and cold ischaemia time (CIT). The postoperative period 
was defined as the 7 days immediately following the date 
of transplant. Data relating to immunosuppressive drug 
regimen, creatinine, insulin, parenteral nutrition (PN), 
continuous veno-venous haemodiafiltration (CVVHDF), 
use of insulin drip, and glucose were measured across the 
postoperative period.
This study conformed to the principles of the Helsinky 
Declaration, and was reviewed and approval by the Local 
Research Committee (code # CEIC2011/328). Written 
inform consent was obtained from all participants.
Glucose measurements
Glucose was determined in fasting plasma samples by the 
glucose oxidase peroxidase method, using an Advia 2400 
autoanalyser from Siemens Healthcare Diagnostics (Bar-
celona, Spain). Blood samples were taken every day at 
7:00 am from a radial arterial catheter or from a periph-
eral venous device if the catheter had been withdrawn 
before day 7.
Approach to insulin and glucose control
There was a specific protocol for the use of insulin or any 
specific target for glucose control during the study. Com-
mencement of insulin was decided by the intensive care 
unit (ICU) medical staff, and insulin dosage was adjusted 
by ICU nurses with the general aim of maintaining glu-
cose levels between 120 and 180 mg/dL (6.6 and 10 mM).
Outcomes and definitions
Patients were classified as known diabetic patients if they 
had been informed of this diagnosis by a physician before 
admission or were on antihyperglycaemic agents, insulin 
or diet therapy. Patients were followed up by the study 
team throughout their hospital stay. After discharge, 
vital status data were obtained by reviewing the National 
Health Registry, by contacting patients or their families 
individually and, in cases where patients had been hospi-
talised, by reviewing the hospital records of major clinical 
events. Patient survival was defined as the period of time 
between transplantation and end of follow-up or death.
Missing data management
The following variables in the data set had missing data: 
MELD (57%); red blood cell requirements (RBC, 0.4%); 
hepatitis C virus (HCV, 0.1%); height (3%); body weight 
(3%); creatinine levels (3%); and cytomegalovirus infec-
tion (1%). To compensate for missing data, chained equa-
tions were used to perform multiple imputations. Both 
complete and incomplete variables were used as predic-
tors during the imputation process.
Statistical analysis
Data are presented as the mean ± SD, or as median (Per-
centil 25, Percentil 75). Differences between groups were 
assessed using U Mann–Whitney test for continuous var-
iables and Chi squared test for categorical variables.
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In view of the different glucose profiles obtained (see 
Fig. 1), independent multivariate Cox models were con-
structed in diabetic and nondiabetic patients. In both 
cases a selection of variables of known prognostic value 
(age, gender, BMI, etiology, MELD, creatinine, CIT, 
RBC and platelets transfusion, PN, and CVVHDF) were 
included. A backward stepwise procedure using Akaike 
Information Criterion was then performed to obtain a 
final model with the selected predictors.
The relationship between glucose profiles and the risk 
of death were modelled by using flexible joint modelling 
of longitudinal data and time-to-event analysis [13]. The 
idea is to construct an appropriate flexible mixed-effects 
model with spline smoothing for describing the evolu-
tion of glucose profiles, and then to use these estimated 
evolutions as a time-dependent covariate in a Cox model. 
The both sub-models can be represented as follows;
Longitudinal sub‑model
log(Glucose)i,diab = (β0 + bi0)+ (β1 + bi1)Bn(t,d1)
+ (β2 + bi2)Bn(t,d2)+ (β3 + bi2)Bn(t,d3)
+ β4agei + β5bmii + β6carci
+ β7THi + β8NPTti + β9meldi + εi
where {Bn(t,  dk); k = 1, 2, 3} denotes a B-spline basis 
matrix for a natural cubic spline [14].
Survival sub‑model
where  h0(t) is a Weibull baseline risk function [15].
Beside the above mentioned models, in order to com-
pare with the joint modelling approach, we conducted 
log(Glucose)i,no−diab = (β0 + bi0)+ (β1 + bi1)Bn(t,d1)
+ (β2 + bi2)Bn(t,d2)+ (β3 + bi2)Bn(t,d3)
+ β4agei + β5carci + β6NPTti




1agei + 2bmii + 3carci + 4THi





1agei + 2carci + 3NPTti + 4bmii
+ 5THi + 6hemofiltroi + αlog(Glucose)i(t)
)
Fig. 1 Subject‑specific trends in glucose measurements and overall smooth (loess smoothing) trends among patients with and without diabetes
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a simple Cox model including a coefficient of variation 
(CV) of the glucose measurements during the first week 
post-OLT.
All the statistical analyses were carried out with the 
statistical software R, version 3.3.1 which is freely avail-
able at cran R webpage. For this purpose, the following 
packages were used: “nlme” for fitting linear mixed mod-
els, “survival” to fit Cox proportional hazards regression 
models, “JM” to perform joint models for longitudinal 
and time-to-event data and “lattice” to visualize glucose 




The 632 patients enrolled in the study were aged 
52 ± 11  years (mean ± SD), 158 (25%) were women, and 
125 (20%) had a history of diabetes. Alcoholic liver dis-
ease was the most common aetiology of OLT, accounting 
for 386 (61%) cases. There were 130 (21%) with HCV, 33 
(5%) with Hepatitis B virus, and 33 (5%) with fulminant 
hepatitis. Carcinoma was present in 174 (28%) patients. 
The median duration of follow-up was 7  years (range 
1–18 years), and 218 patients (34%) died. The sample had 
a survival rate of 85% at 1 year and 65% at 10 years.
At 1  year of follow-up, survivors were younger than 
non-survivors (51 ± 11 vs. 55 ± 12  years, P < 0.001) 
and registered a lower MELD score (13 ± 6 vs. 17 ± 8, 
P < 0.001). Patients who had higher transfusion require-
ments and required CVVHDF registered a higher mor-
tality, as did those with longer parenteral nutrition. 
Baseline and postoperative characteristics in relation to 
death at 1 year of follow-up are summarised in Table 1.
Glucose levels, diabetes and mortality
Figure  1 shows overall glucose profiles for diabetic and 
non-diabetic patients. Patients with diabetes had higher 
levels of pre-operative glucose than did those with-
out diabetes. Among diabetic patients, glucose levels 
declined gradually from day 1, whereas among non-dia-
betic patients glucose levels rose until reaching a peak on 
days 2–3 and then declined to their former levels over the 
course of the following days.
The main characteristics of diabetic and non-diabetic 
patients are shown in Table  2. Briefly, diabetic patients 
were older, had fewer transfusion requirements and lower 
MELD scores than did their non-diabetic counterparts. 
Alcoholic liver disease and malignant aetiology were also 
more frequent causes of OLT in diabetic patients.
Table 1 Baseline and postoperative characteristics of patients, according to vital status (after 1-year follow-up)
Data are expressed as mean ± SD or medians [25th percentile, 75th percentile]
Pre-operative glucose and creatinine levels are shown
BMI body mass index, CIT cold ischaemia time, CVVHDF continuous veno-venous haemodiafiltration, HCV hepatitis C virus, MELD Model for End-stage Liver Disease 
score, PN parenteral nutrition, PT platelet requirements, RBC red blood cell requirements
Variable Survivors at 1 year (n = 542) Non-survivors at 1 year (n = 90) P value
Age, years 51 ± 11 55 ± 12 0.001
Males, n (%) 416 (77) 58 (64) 0.012
Body mass index, kg/m2 26.9 ± 3.9 26.5 ± 3.4 0.288
Diabetes, n (%) 111 (20) 14 (16) 0.513
Aetiology, n (%)
 Alcohol 338 (62) 48 (53) 0.220
 HCV 109 (20) 21 (23) 0.484
 Malignant 143 (26) 31 (34) 0.113
 Fulminant 24 (4) 9 (10) 0.021
MELD 13 ± 6 17 ± 8 < 0.001
Glucose, mg/dL 130 ± 74 128 ± 72 0.709
Creatinine, mg/dL 0.9 ± 0.5 0.9 ± 0.4 0.221
CIT, hours 7.5 ± 2.2 7.7 ± 2.2 0.330
RBC transfusion, units 5 [2, 10] 10 [4, 17] < 0.001
PT, units 0 [0, 1] 0 [0, 2] 0.170
PN, days 4 [3, 6] 6 [4, 10] < 0.001
CVVHDF, n (%) 60 (11) 17 (18) 0.044
Metilprednisolona 537 (99) 89 (99) 0.759
Tacrolimus 444 (83) 89 (99) 0.058
Ciclosporina 161 (30) 20 (22) 0.156
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Patients with diabetes registered a survival rate of 89% 
at 1 year and 68% at 10 years, figures similar to those for 
patients without diabetes (86 and 65% respectively).
Among patients with diabetes, the results of the Cox 
proportional hazards analysis showed a significant 
association between mortality and age, MELD score and 
HCV. Among non-diabetic patients a significant increase 
in mortality was observed among individuals who were 
older or presented with malignant aetiology, more 
transfusion requirements and more time of parenteral 
nutrition.
Joint modelling showed that glucose profiles taken 
during the first week post-transplantation were associ-
ated with mortality among patients without diabetes 
(P = 0.022), with this association not being found among 
those previously diagnosed with diabetes (P = 0.689) 
(Tables 3 and 4).
Regarding the interpretation of the glucose profiles, it 
is getting compromised. For its interpretation, we should 
take a look not only the intercept which is the baseline 
glucose level but at the profiles assessing their evolutions. 
As can be seen in Fig. 2, mortality is higher in individuals 
Table 2 Characteristics of patients, according to diabetes 
status
Data are expressed as mean ± SD or medians [25th percentile, 75th percentile]
Pre-operative glucose and creatinine levels are shown
BMI body mass index, CIT cold ischaemia time, CVVHDF continuous veno-venous 
haemodiafiltration, HCV hepatitis C virus, MELD Model for End-stage Liver 








Age, years 56 ± 8 51 ± 12 < 0.001
Males, n (%) 102 (81) 372 (73) 0.074
Body mass index, 
kg/m2
27.4 ± 3.6 26.7 ± 3.8 0.029
Aetiology, n (%)
 Alcohol 88 (70) 298 (58) 0.022
 HCV 28 (22) 102 (20) 0.659
 Malignant 52 (41) 122 (24) < 0.001
 Fulminant 2 (2) 31 (6) 0.070
MELD 13 ± 5 14 ± 6 0.044
Glucose, mg/dL 207 ± 108 111 ± 43 < 0.001
Creatinine, mg/dL 0.9 ± 0.4 0.9 ± 0.4 0.532
CIT, hours 7.5 ± 2.6 7.4 ± 2.1 0.252
RBC transfusion, 
units
5 [2, 9] 6 [3, 12] 0.034
PT, units 0 [0, 1] 0 [0, 1] 0.079
PN, days 4 [3, 6] 4 [3, 6] 0.788
CVVHDF, n (%) 20 (16) 57 (11) 0.192
Table 3 Survival model for patients without diabetes
HR (95% CI) means hazard ratio (95% confidence interval)
BMI body mass index, RBC red blood cells, PN parenteral nutrition, CVVHDF 
continuous veno-venous haemodiafiltration, CV coefficient of variation
Cox model Joint model
HR (95% CI) P value HR (95% CI) P value
Age, years 1.02 (1.00, 1.03) 0.001 1.02 (1.00, 1.03) 0.006
BMI, kg/m2 0.95 (0.91, 1.00) 0.033 0.96 (0.92, 1.00) 0.080
Malignant 1.49 (1.04, 2.13) 0.034 1.59 (1.11, 2.29) 0.011
RBC, units 1.02 (1.01, 2.01) < 0.001 1.02 (1.01, 1.03) < 0.001
PN, days 1.01 (1.00, 1.03) < 0.001 1.06 (1.04, 1.08) < 0.001
CVVHDF 2.29 (1.53, 3.42) < 0.001 1.08 (0.65, 1.78) 0.768
Glucose profiles – – See Fig. 1 0.022
Glucose variabil‑
ity (CV)
2.71 (0.72, 10.15) 0.13 – –
Table 4 Survival model for patients with diabetes
The results of the joint models are expressed as hazard ratios with their 
corresponding confidence intervals. In any case where non-linear trends in 
glucose levels are a covariate in the survival process, interpretation of the 
coefficients of association (α) becomes compromised. Accordingly, only the 
levels of significance (P values) of the coefficients of association are shown
HR (95% CI) means hazard ratio (95% confidence interval)
MELD Model for End-stage Liver Disease score, HCV hepatitis C virus, CV 
coefficient of variation
Cox model Joint model
HR (95% CI) P value HR (95% CI) P value
Age, years 1.03 (0.98, 1.08) 0.048 1.07 (1.02, 1.12) 0.005
MELD score 1.02 (0.96, 1.09) 0.016 1.07 (1.01, 1.14) 0.016
HCV 2.19 (1.13, 4.23) 0.020 2.36 (1.21, 4.57) 0.010
Glucose profiles – – See Fig. 1 0.689
Glucose variability 
(CV)
0.20 (0.01, 3.57) 0.27 – –
Fig. 2 Overall smooth (loess smoothing) trends among patients who 
dead in the first year and those who did not
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at higher glucose levels after 48–72  h post-OLT, also 
showing a worse response to the insulin treatment within 
the first week.
While statistically significant association between glu-
cose and mortality is found when using glucose profiles, 
it is not found when using a summary measure of glucose 
variability such as CV.
Discussion
In this survival study among OLT patients, the main find-
ings were: (1) plasma glucose profiles during the first 
week post-OLT are different in patients with and with-
out diabetes mellitus prior to transplantation; (2) while 
glucose levels are associated with a higher risk of mor-
tality among patients without diabetes, after adjusting 
for potential confounding variables such as age, cause of 
transplantation, MELD, BMI, nutrition, and haemodiafil-
tration, this does not occur among patients with diabe-
tes; and, (3) the glucose profiles analysis provides better 
information than a single measure of glucose variability 
to ascertain the relationship between glucose levels and 
mortality.
The fact that glucose values may give rise to an increase 
in long-term mortality among critical patients has been 
previously described. The association between glucose 
and mortality has been the subject of study by a num-
ber of authors [16–20], though not all report uniform 
results. Some authors observe that in many diseases, crit-
ical patients having higher glucose levels register higher 
mortality [21–24], something that has led in turn to the 
implementation of different protocols aimed at achiev-
ing a strict control of glycaemia, so as to maintain glu-
cose values within the range of normality. Such strict 
control does not necessarily entail a decrease in mortal-
ity, however. Indeed, in some patients this has even been 
observed to lead to an increase in mortality, possibly due 
to a higher rate of hypoglycaemia [25–28].
With respect to glucose levels, there are also reports 
of different mortality patterns observed in patients with 
and without diabetes. Patients with diabetes tolerate 
higher glycaemic values, without repercussions on mor-
tality, conceivably possessing some, as yet unknown, 
protective factors against stress hyperglycaemia. These 
facts, together with the finding that in the first week 
post-OLT diabetic patients display glucose profiles dif-
ferent to those of non-diabetic patients, led us to analyse 
these two groups of patients separately. As can be seen 
from Fig.  1, patients with diabetes started with higher 
plasma glucose values on the first day, which then gradu-
ally declined after the first 48 h. In contrast, non-diabetic 
patients started from appreciably lower figures which 
gradually rose until reaching a peak at 48–72 h, and then 
subsequently declined (all within the context of insulin 
being administered via continuous perfusion).
This agrees with the results of previous studies in 
which the presence of diabetes has been reported to 
afford a protective effect against hyperglycaemia [29–31]; 
hence, despite the fact that patients with diabetes display 
higher glycaemic values, this would not affect mortality. 
This might perhaps be attributable to the existence of a 
chronic state of hyperglycaemia in such patients, which 
would confer a greater tolerance to the condition and 
so attenuate its harmful effects in  situations of stress. 
Already in Egi’s study, it was observed that, even within 
the group of patients with diabetes, those who presented 
with higher glycated haemoglobin figures, with worse 
control of their disease, and had thus chronically main-
tained higher glucose figures, would tolerate hypergly-
caemia better [32].
Despite the many studies conducted on glycaemia in a 
critical care setting, very few references could be found 
in the field of liver transplantation [33–35], and none of 
them stratified patients into those with and those without 
diabetes. Furthermore, when glycaemic levels were stud-
ied, consideration was given only to isolated glycaemic 
values or summary values of variability, such as standard 
deviation [36] or the coefficient of variation [29], with no 
follow-up of glycaemia across time having been previ-
ously conducted as in our study. Moreover, joint-mod-
elling analysis allows for a better approximation of the 
survival of such patients, by taking trends in glycaemic 
levels in the postoperative period into account.
Similarly, patients with diabetes display higher absolute 
glycaemic values than do patients without diabetes dur-
ing the first 7 days after transplantation. Although glycae-
mia does not attain such high values in patients without 
diabetes, glycaemic levels nevertheless display a marked 
rise at day 3, which is absent among diabetics and could 
reflect glycaemic response to stress. Despite insulin being 
administered via continuous perfusion to maintain gly-
caemia figures between 120 and 180  mg/dL, the distri-
bution adopted by glycaemia remained unchanged. This 
coupled with the fact that glycaemic profiles were asso-
ciated with mortality solely in patients without diabetes, 
led us to think that the presence of this hyperglycaemic 
peak might possibly flag patients with the highest stress—
and thus the most severe patients—and not glycaemic 
levels per se. This may be compatible with findings of 
previous studies in which correction of hyperglycaemia 
was observed to lead to an increase in hypoglycaemia 
and mortality rates. It is for this reason that, on evaluat-
ing glycaemia in post-OLT patients, we feel that account 
should be taken, not only of the glycaemic values but also 
of their trend over time, distinguishing between patients 
with and those without diabetes.
Page 7 of 8Giráldez et al. Diabetol Metab Syndr  (2018) 10:35 
Limitations of the study
The use of MELD as a severity score was introduced 
only from 2002 onwards thus having the measurements 
available in only 43% of patients. The use of this score is 
supported by many studies and liver transplantation soci-
eties, which consider it not only a predictor of waiting list 
mortality, but also a possible factor of post-OLT mortal-
ity [37], since it identifies patients with a higher risk of 
renal failure, perioperative bleeding and more transfu-
sion requirements. Hence, Matthews study observed 
that for every 5-point rise in the MELD score there was 
an increase of 15 units in RBC requirements, and every 
10 units of platelet concentrate transfused increased the 
risk of post-OLT renal failure by 5–8% and amounted to a 
significant increase in perioperative morbidity and mor-
tality [38]. Although contradictory results has been found 
in other studies [37]. In our study, we have chosen to 
perform multiple imputation techniques given that tra-
ditional complete case analysis suffers from inefficiency, 
selection bias of subjects and other limitations. In addi-
tion, we also performed analyses estimating MELD score 
from prothrombin values in patients who underwent 
liver transplantation before 2002. Results of these analy-
ses showed similar results from those obtained by per-
forming multiple imputation methods (data not shown).
The time at surgery is an important predictor for the 
risk of death that was not included into the predictive 
model. In the final model, transfusion requirements; 
operating time, cold ischaemia time (CIT), changes in 
nutrition were entered. All these covariates are associ-
ated with the time of surgery which can contribute more 
information than the global time effect. In addition, the 
regression models containing all these covariates and 
time variable may suffer from collinearity which degrades 
the precision of estimate coefficients for the reason of 
having a strong interaction between them.
A further limitation of the study was the use of con-
tinuous insulin perfusion, which modified the glycae-
mic readings. Even so, it has to be said that insulin was 
administered to all patients in accordance with the same 
protocol.
This study may have clinical implications of relevance: 
firstly, glycaemic levels in patients with and without 
diabetes should not be considered in the same way, i.e., 
patients with diabetes appear to tolerate higher glycaemic 
figures without repercussions on their mortality; and sec-
ondly, trends in glucose levels during the first days post-
OLT may well be of importance in terms of mortality.
Conclusions
Glucose profiles during the first week after liver trans-
plantation are associated with long-term mortality in 
patients without diabetes, after adjusting for potential 
confounding variables such as age, cause of transplanta-
tion, MELD, nutrition, immunosuppressive drugs, and 
units of insulin administered. Furthermore, these profiles 
are different in patients with and without diabetes.
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